ANCA-Associated Vasculitis

被引:1
|
作者
Sharma, Purva [1 ]
Zonozi, Reza [2 ,3 ]
Geetha, Duvuru [4 ]
机构
[1] Northwell Hlth, Glomerular Ctr, Div Kidney Dis & Hypertens, Great Neck, NY USA
[2] Nephrol Associates Northern Virginia, Fairfax, VA USA
[3] Inova Fairfax Hosp, Falls Church, VA USA
[4] Johns Hopkins Univ, Sch Med, Div Nephrol, Baltimore, MD USA
来源
ADVANCES IN KIDNEY DISEASE AND HEALTH | 2024年 / 31卷 / 03期
关键词
ANCA; Rituximab; Plasmapheresis; Vasculitis; ANTIBODY-ASSOCIATED VASCULITIS; RHEUMATOLOGY CLASSIFICATION CRITERIA; 2022; AMERICAN-COLLEGE; ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; DAILY ORAL CYCLOPHOSPHAMIDE; RANDOMIZED-TRIAL; PLASMA-EXCHANGE; RENAL SURVIVAL; CRESCENTIC GLOMERULONEPHRITIS; WEGENERS-GRANULOMATOSIS;
D O I
10.1053/j.akdh.2024.04.005
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
ANCA-associated vasculitis (AAV) is a necrotizing, small-to-medium vessel vasculitis associated with significant morbidity and mortality. AAV is a systemic autoimmune disease affecting kidneys, eyes, sinuses, peripheral nerves, skin, and upper and lower respiratory tracts. AAV tends to present in characteristic phenotypes categorized clinically as granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic GPA (EGPA). Kidney involvement is a common feature of AAV, and has important implications on disease prognosis and management. Existing therapies have been refined and improvements in our understanding of the pathophysiology of AAV has led to approval of novel therapies. In this review, we provide an overview of epidemiology, disease mechanisms, clinical presentation and review therapeutic strategies for induction and maintenance of remission.
引用
收藏
页码:194 / 205
页数:12
相关论文
共 50 条
  • [41] Treatment of ANCA-associated vasculitis
    Ulf Schönermarck
    Wolfgang L. Gross
    Kirsten de Groot
    Nature Reviews Nephrology, 2014, 10 : 25 - 36
  • [42] Spectrum of ANCA-Associated Vasculitis
    Sinha, Aditi
    Bagga, Arvind
    INDIAN JOURNAL OF PEDIATRICS, 2017, 84 (10): : 737 - 738
  • [43] Rituximab in ANCA-Associated Vasculitis
    Romina I. Hassan
    Angelo L. Gaffo
    Current Rheumatology Reports, 2017, 19
  • [44] The immunopathology of ANCA-associated vasculitis
    Eoin F. McKinney
    Lisa C. Willcocks
    Verena Broecker
    Kenneth G. C. Smith
    Seminars in Immunopathology, 2014, 36 : 461 - 478
  • [45] Rituximab in ANCA-Associated Vasculitis
    Hassan, Romina I.
    Gaffo, Angelo L.
    CURRENT RHEUMATOLOGY REPORTS, 2017, 19 (02)
  • [46] Pathogenesis of ANCA-associated Vasculitis
    Flint, Julia
    Morgan, Matthew D.
    Savage, Caroline O. S.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2010, 36 (03) : 463 - +
  • [47] Updates in ANCA-associated vasculitis
    Ross, Carolyn
    Makhzoum, Jean-Paul
    Pagnoux, Christian
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2022, 9 (03) : 153 - 166
  • [48] Biomarkers in ANCA-Associated Vasculitis
    Lally, Lindsay
    Spiera, Robert F.
    CURRENT RHEUMATOLOGY REPORTS, 2013, 15 (10)
  • [49] ANCA-Associated Vasculitis: An Update
    Almaani, Salem
    Fussner, Lynn A.
    Brodsky, Sergey
    Meara, Alexa S.
    Jayne, David
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (07)
  • [50] The Future of ANCA-associated Vasculitis
    Holle, Julia U.
    Wieczorek, Stefan
    Gross, Wolfgang L.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2010, 36 (03) : 609 - +